Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan AW, Orkin A, Gill P, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg P, Weijer C, Simes J, Rombey T, Williams H, Wittes J, Moher D, Richards D, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala A, Schulz K, Calleja S, Boutron I, Ross J, Golub R, Khan K, Mulrow C, Siegfried N, Heber J, Lee N, Kearney P, Wanyenze R, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan A, Kiermer V, Corrigan-Curay J, Concato J. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances. JAMA 2021, 326: 257-265. PMID: 34152382, DOI: 10.1001/jama.2021.9941.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements